Soleno Therapeutics Investors Face Class Action Opportunity
Investors in Soleno Therapeutics (NASDAQ: SLNO) who have experienced significant losses now have an opportunity to participate in a class action lawsuit. The national shareholder rights law firm Hagens Berman is spearheading the case on behalf of investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025 (the “Class Period”). With the lead plaintiff deadline of May 5, 2026, fast approaching, those affected by the alleged misconduct are encouraged to understand their rights and options regarding this class action lawsuit.
Key Allegations Against Soleno Therapeutics
The class action lawsuit centers on allegations that Soleno Therapeutics misrepresented the safety and commercial viability of its flagship drug, VYKAT™ XR (DCCR), intended for the treatment of Prader-Willi syndrome (PWS). The complaint asserts that during the Class Period, Soleno provided repeated assurances about the safety, efficacy, and anticipated market success of DCCR, while allegedly failing to disclose critical information to investors:
- Safety Concerns: The company is accused of downplaying evidence of serious safety risks, including fluid retention and potential heart failure in children treated with DCCR.
- Data Integrity Issues: A report from activist short seller Scorpion Capital highlighted irregularities in clinical trial data, raising suspicions about the reliability of results and the involvement of a controversial physician in Gainesville, Florida.
- Inflated Metrics: Soleno reportedly exaggerated the initial commercial success of DCCR by citing artificially boosted “start forms,” which were allegedly driven by factors other than genuine market demand.
Timeline of Disclosures and Stock Impact
On August 15, 2025, Scorpion Capital released a report titled “Russian Roulette With Prader-Willi Children,” which detailed adverse patient reactions and skepticism among clinical investigators. Following the release, Soleno’s stock price suffered a double-digit decline, reflecting investor concern over the allegations.
The situation intensified on November 4, 2025, when Soleno reported its third-quarter financial results. Company management acknowledged that the DCCR launch was disrupted, with lower patient enrollment and an increase in treatment discontinuations. This admission resulted in a 27% single-day drop in the price of SLNO shares.
Lead Plaintiff Deadline and Investor Actions
Investors who purchased Soleno shares during the Class Period and experienced substantial losses have until May 5, 2026, to seek appointment as lead plaintiff in the class action lawsuit. Serving as lead plaintiff provides investors with the opportunity to influence litigation strategy and potential recovery. Those with significant losses or relevant information are urged to contact Hagens Berman to discuss the case or submit their claims.
Whistleblower Incentives and Legal Support
Individuals possessing non-public information about Soleno’s conduct are also encouraged to consider their options. The SEC Whistleblower Program may provide rewards of up to 30% of any successful recovery based on original information that leads to enforcement action. Hagens Berman offers guidance to potential whistleblowers regarding participation in the program and the protections available to them.
About Hagens Berman
Hagens Berman is a global law firm specializing in complex litigation and corporate accountability. The firm represents investors, whistleblowers, and other parties harmed by corporate misconduct. With a track record of securing over $2.9 billion for clients, Hagens Berman is recognized for its role in shareholder and class action cases. More information about the firm’s work and updates on ongoing cases can be found on their website and social media channels.
Conclusion: Understanding Your Rights in the Soleno Class Action Lawsuit
The class action lawsuit against Soleno Therapeutics underscores the importance of corporate transparency and investor protection. Those affected by the alleged misrepresentations and resulting financial losses should carefully review their legal options before the May 5, 2026, deadline. By participating in the class action, investors can help hold companies accountable and potentially recover losses incurred during the Class Period.
This article is inspired by content from Original Source. It has been rephrased for originality. Images are credited to the original source.